<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34757590</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1182</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Molecular neurobiology</Title><ISOAbbreviation>Mol Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>683</StartPage><EndPage>702</EndPage><MedlinePgn>683-702</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12035-021-02557-w</ELocationID><Abstract><AbstractText>Understanding the mechanisms underlying amyotrophic lateral sclerosis (ALS) is crucial for the development of new therapies. Previous studies have demonstrated that mitochondrial dysfunction is a key pathogenetic event in ALS. Interestingly, studies in Alzheimer's disease (AD) post-mortem brain and animal models link alterations in mitochondrial function to interactions between hyperphosphorylated tau and dynamin-related protein 1 (DRP1), the GTPase involved in mitochondrial fission. Recent evidence suggest that tau may be involved in ALS pathogenesis, therefore, we sought to determine whether hyperphosphorylated tau may lead to mitochondrial fragmentation and dysfunction in ALS and whether reducing tau may provide a novel therapeutic approach. Our findings demonstrated that pTau-S396 is mis-localized to synapses in post-mortem motor cortex (mCTX) across ALS subtypes. Additionally, the treatment with ALS synaptoneurosomes (SNs), enriched in pTau-S396, increased oxidative stress, induced mitochondrial fragmentation, and altered mitochondrial connectivity without affecting cell survival in vitro. Furthermore, pTau-S396 interacted with DRP1, and similar to pTau-S396, DRP1 accumulated in SNs across ALS subtypes, suggesting increases in mitochondrial fragmentation in ALS. As previously reported, electron microscopy revealed a significant decrease in mitochondria density and length in ALS mCTX. Lastly, reducing tau levels with QC-01-175, a selective tau degrader, prevented ALS SNs-induced mitochondrial fragmentation and oxidative stress in vitro. Collectively, our findings suggest that increases in pTau-S396 may lead to mitochondrial fragmentation and oxidative stress in ALS and decreasing tau may provide a novel strategy to mitigate mitochondrial dysfunction in ALS. pTau-S396 mis-localizes to synapses in ALS. ALS synaptoneurosomes (SNs), enriched in pTau-S396, increase oxidative stress and induce mitochondrial fragmentation in vitro. pTau-S396 interacts with the pro-fission GTPase DRP1 in ALS. Reducing tau with a selective degrader, QC-01-175, mitigates ALS SNs-induced mitochondrial fragmentation and increases in oxidative stress in vitro.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Petrozziello</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bordt</LastName><ForeName>Evan A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Alexandra N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Spencer E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sapp</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devlin</LastName><ForeName>Benjamin A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Psychology and Neuroscience, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obeng-Marnu</LastName><ForeName>Abigail A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farhan</LastName><ForeName>Sali M K</ForeName><Initials>SMK</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amaral</LastName><ForeName>Ana C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dujardin</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dooley</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henstridge</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Systems Medicine, Neuroscience, Ninewells hospital &amp; Medical School, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oakley</LastName><ForeName>Derek H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neueder</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spires-Jones</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilbo</LastName><ForeName>Staci D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02129, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology and Neuroscience, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vakili</LastName><ForeName>Khashayar</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, Boston Children's Hospital, Boston, MA, 02125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiFiglia</LastName><ForeName>Marian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>M Catarina</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haggarty</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadri-Vakili</LastName><ForeName>Ghazaleh</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3435-3544</Identifier><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, MA, 02129, USA. gsadrivakili@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Bldg 114 16th Street, R2200, Charlestown, MA, 02129, USA. gsadrivakili@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Neurobiol</MedlineTA><NlmUniqueID>8900963</NlmUniqueID><ISSNLinking>0893-7648</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Hyperphosphorylated tau</Keyword><Keyword MajorTopicYN="N">Mitochondrial dynamics</Keyword><Keyword MajorTopicYN="N">Mitochondrial dysfunction</Keyword><Keyword MajorTopicYN="N">Tau degrader</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>10</Day><Hour>16</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34757590</ArticleId><ArticleId IdType="doi">10.1007/s12035-021-02557-w</ArticleId><ArticleId IdType="pii">10.1007/s12035-021-02557-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377(2):162&#x2013;172</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, Gitler AD (2020) ALS genetics: gains, losses, and implications for future therapies. Neuron 108(5):822&#x2013;842</Citation><ArticleIdList><ArticleId IdType="pubmed">32931756</ArticleId><ArticleId IdType="pmc">7736125</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodakuntla S, Jijumon AS, Villablanca C, Gonzalez-Billault C, Janke C (2019) Microtubule-associated proteins: structuring the cytoskeleton. Trends Cell Biol 29(10):804&#x2013;819</Citation><ArticleIdList><ArticleId IdType="pubmed">31416684</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura S, Wate R, Kaneko S, Ito H, Oki M, Tsuge A et al (2014) An autopsy case of sporadic amyotrophic lateral sclerosis associated with the I113T SOD1 mutation. Neuropathology 34(1):58&#x2013;63</Citation><ArticleIdList><ArticleId IdType="pubmed">23773010</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi R, Toyoshima Y, Tada M, Tanaka H, Shimizu H, Shiga A et al (2016) Globular glial mixed four repeat Tau and TDP-43 proteinopathy with motor neuron disease and frontotemporal dementia. Brain Pathol 26(1):82&#x2013;94</Citation><ArticleIdList><ArticleId IdType="pubmed">25787090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayaki T, Ito H, Komure O, Kamada M, Nakamura M, Wate R et al (2018) Multiple proteinopathies in familial ALS cases with optineurin mutations. J Neuropathol Exp Neurol 77(2):128&#x2013;138</Citation><ArticleIdList><ArticleId IdType="pubmed">29272468</ArticleId></ArticleIdList></Reference><Reference><Citation>Moszczynski AJ, Hintermayer MA, Strong MJ (2018) Phosphorylation of threonine 175 Tau in the induction of Tau pathology in amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD). A review. Front Neurosci 12:259</Citation><ArticleIdList><ArticleId IdType="pubmed">29731706</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens CH, Guthrie NJ, van Roijen M, Halliday GM, Ooi L (2019) Increased Tau phosphorylation in motor neurons from clinically pure sporadic amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol 78(7):605&#x2013;614</Citation><ArticleIdList><ArticleId IdType="pubmed">31131395</ArticleId><ArticleId IdType="pmc">7967836</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ZX, Tan L, Yu JT (2015) Axonal transport defects in Alzheimer&#x2019;s disease. Mol Neurobiol 51(3):1309&#x2013;1321</Citation><ArticleIdList><ArticleId IdType="pubmed">25052480</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoothoff W, Jones PB, Spires-Jones TL, Joyner D, Chhabra E, Bercury K et al (2009) Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport. J Neurochem 111(2):417&#x2013;427</Citation><ArticleIdList><ArticleId IdType="pubmed">19686388</ArticleId><ArticleId IdType="pmc">2831412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopeikina KJ, Carlson GA, Pitstick R, Ludvigson AE, Peters A, Luebke JI et al (2011) Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol 179(4):2071&#x2013;2082</Citation><ArticleIdList><ArticleId IdType="pubmed">21854751</ArticleId><ArticleId IdType="pmc">3181340</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahpasand K, Uemura I, Saito T, Asano T, Hata K, Shibata K et al (2012) Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease. J Neurosci 32(7):2430&#x2013;2441</Citation><ArticleIdList><ArticleId IdType="pubmed">22396417</ArticleId><ArticleId IdType="pmc">6621814</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Martin T, Cuchillo-Ibanez I, Noble W, Nyenya F, Anderton BH, Hanger DP (2013) Tau phosphorylation affects its axonal transport and degradation. Neurobiol Aging 34(9):2146&#x2013;2157</Citation><ArticleIdList><ArticleId IdType="pubmed">23601672</ArticleId><ArticleId IdType="pmc">3684773</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabezas-Opazo FA, Vergara-Pulgar K, Perez MJ, Jara C, Osorio-Fuentealba C, Quintanilla RA (2015) Mitochondrial dysfunction contributes to the pathogenesis of Alzheimer&#x2019;s disease. Oxid Med Cell Longev 2015:509654</Citation><ArticleIdList><ArticleId IdType="pubmed">26221414</ArticleId><ArticleId IdType="pmc">4499633</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickett EK, Rose J, McCrory C, McKenzie CA, King D, Smith C et al (2018) Region-specific depletion of synaptic mitochondria in the brains of patients with Alzheimer's disease. Acta Neuropathol 136(5):747&#x2013;757</Citation><ArticleIdList><ArticleId IdType="pubmed">30191401</ArticleId><ArticleId IdType="pmc">6208730</ArticleId></ArticleIdList></Reference><Reference><Citation>Alavi Naini SM, Soussi-Yanicostas N (2015) Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies? Oxid Med Cell Longev 2015:151979</Citation><ArticleIdList><ArticleId IdType="pubmed">26576216</ArticleId><ArticleId IdType="pmc">4630413</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Bai F (2018) The Association of Tau with mitochondrial dysfunction in Alzheimer&#x2019;s disease. Front Neurosci. 12:163</Citation><ArticleIdList><ArticleId IdType="pubmed">29623026</ArticleId><ArticleId IdType="pmc">5874499</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez MJ, Jara C, Quintanilla RA (2018) Contribution of Tau pathology to mitochondrial impairment in neurodegeneration. Front Neurosci 12:441</Citation><ArticleIdList><ArticleId IdType="pubmed">30026680</ArticleId><ArticleId IdType="pmc">6041396</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilokani L, Nagashima S, Paupe V, Prudent J (2018) Mitochondrial dynamics: overview of molecular mechanisms. Essays Biochem 62(3):341&#x2013;360</Citation><ArticleIdList><ArticleId IdType="pubmed">30030364</ArticleId><ArticleId IdType="pmc">6056715</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M, Reddy PH (2012) Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet 21(11):2538&#x2013;2547</Citation><ArticleIdList><ArticleId IdType="pubmed">22367970</ArticleId><ArticleId IdType="pmc">3349426</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandimalla R, Manczak M, Fry D, Suneetha Y, Sesaki H, Reddy PH (2016) Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer&#x2019;s disease. Hum Mol Genet 25(22):4881&#x2013;4897</Citation><ArticleIdList><ArticleId IdType="pubmed">28173111</ArticleId><ArticleId IdType="pmc">6078590</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z, Wang W, Perry G, Zhu X, Wang X (2015) Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis. Transl Neurodegener 4:14</Citation><ArticleIdList><ArticleId IdType="pubmed">26225210</ArticleId><ArticleId IdType="pmc">4518588</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EF, Shaw PJ, De Vos KJ (2019) The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett 710:132933</Citation><ArticleIdList><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Calio ML, Henriques E, Siena A, Bertoncini CRA, Gil-Mohapel J, Rosenstock TR (2020) Mitochondrial dysfunction, neurogenesis, and epigenetics: putative implications for amyotrophic lateral sclerosis neurodegeneration and treatment. Front Neurosci 14:679</Citation><ArticleIdList><ArticleId IdType="pubmed">32760239</ArticleId><ArticleId IdType="pmc">7373761</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrador E, Salvador R, Lopez-Blanch R, Jihad-Jebbar A, Valles SL, Estrela JM (2020) Oxidative Stress, Neuroinflammation and Mitochondria in the Pathophysiology of Amyotrophic Lateral Sclerosis. Antioxidants (Basel) 9(9):901</Citation></Reference><Reference><Citation>Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM (1999) Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 46(5):787&#x2013;790</Citation><ArticleIdList><ArticleId IdType="pubmed">10553999</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemann FR, Manfredi G, Mawrin C, Beal MF, Schon EA (2002) Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem 80(4):616&#x2013;625</Citation><ArticleIdList><ArticleId IdType="pubmed">11841569</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Iwata M (2007) Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 66(1):10&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pubmed">17204932</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsumi T (1981) The ultrastructure of intramuscular nerves in amyotrophic lateral sclerosis. Acta Neuropathol 55(3):193&#x2013;198</Citation><ArticleIdList><ArticleId IdType="pubmed">7349578</ArticleId></ArticleIdList></Reference><Reference><Citation>Vielhaber S, Kunz D, Winkler K, Wiedemann FR, Kirches E, Feistner H et al (2000) Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain 123(Pt 7):1339&#x2013;1348</Citation><ArticleIdList><ArticleId IdType="pubmed">10869047</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ (2011) Mitochondrial pathobiology in ALS. J Bioenerg Biomembr 43(6):569&#x2013;579</Citation><ArticleIdList><ArticleId IdType="pubmed">22083126</ArticleId><ArticleId IdType="pmc">4131252</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT (2012) The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 181(4):1426&#x2013;1435</Citation><ArticleIdList><ArticleId IdType="pubmed">22867711</ArticleId><ArticleId IdType="pmc">3463637</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrozziello T, Mills AN, Vaine CA, Penney EB, Fernandez-Cerado C, Legarda GPA et al (2020) Neuroinflammation and histone H3 citrullination are increased in X-linked Dystonia Parkinsonism post-mortem prefrontal cortex. Neurobiol Dis 144:105032</Citation><ArticleIdList><ArticleId IdType="pubmed">32739252</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge CM, Sideris DI, Carroll E, Rotariu S, Salomonsson S, Tzioras M et al (2018) Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis. Acta Neuropathol 135(2):213&#x2013;226</Citation><ArticleIdList><ArticleId IdType="pubmed">29273900</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller KA, Glajch KE, Huizenga MN, Wilson RA, Granucci EJ, Dios AM et al (2018) Hippo signaling pathway dysregulation in human Huntington&#x2019;s disease brain and neuronal stem cells. Sci Rep 8(1):11355</Citation><ArticleIdList><ArticleId IdType="pubmed">30054496</ArticleId><ArticleId IdType="pmc">6063913</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva MC, Ferguson FM, Cai Q, Donovan KA, Nandi G, Patnaik D et al (2019) Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. Elife 8:e45457</Citation><ArticleIdList><ArticleId IdType="pubmed">30907729</ArticleId><ArticleId IdType="pmc">6450673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Geng J, Gao J, Zhao H, Li J, Shi Y et al (2019) Macrophage achieves self-protection against oxidative stress-induced ageing through the Mst-Nrf2 axis. Nat Commun 10(1):755</Citation><ArticleIdList><ArticleId IdType="pubmed">30765703</ArticleId><ArticleId IdType="pmc">6376064</ArticleId></ArticleIdList></Reference><Reference><Citation>Iijima-Ando K, Sekiya M, Maruko-Otake A, Ohtake Y, Suzuki E, Lu B et al (2012) Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1. PLoS Genet. 8(8):e1002918</Citation><ArticleIdList><ArticleId IdType="pubmed">22952452</ArticleId><ArticleId IdType="pmc">3431335</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos KJ, Chapman AL, Tennant ME, Manser C, Tudor EL, Lau KF et al (2007) Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum Mol Genet 16(22):2720&#x2013;2728</Citation><ArticleIdList><ArticleId IdType="pubmed">17725983</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotelo-Silveira JR, Lepanto P, Elizondo V, Horjales S, Palacios F, Martinez-Palma L et al (2009) Axonal mitochondrial clusters containing mutant SOD1 in transgenic models of ALS. Antioxid Redox Signal 11(7):1535&#x2013;1545</Citation><ArticleIdList><ArticleId IdType="pubmed">19344250</ArticleId><ArticleId IdType="pmc">2842590</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, Unger T et al (2011) Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest 121(2):726&#x2013;738</Citation><ArticleIdList><ArticleId IdType="pubmed">21206091</ArticleId><ArticleId IdType="pmc">3026736</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J, Wils H, Kleinberger G, Joris G, Cuijt I, Ceuterick-de Groote C et al (2013) Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol Neurobiol 48(1):22&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pubmed">23475610</ArticleId><ArticleId IdType="pmc">3718993</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrane J, Cortez C, Gan WB, Manfredi G (2014) Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum Mol Genet 23(6):1413&#x2013;1424</Citation><ArticleIdList><ArticleId IdType="pubmed">24154542</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek SH, Park SJ, Jeong JI, Kim SH, Han J, Kyung JW et al (2017) Inhibition of Drp1 ameliorates synaptic depression, Abeta deposition, and cognitive impairment in an Alzheimer&#x2019;s disease model. J Neurosci 37(20):5099&#x2013;5110</Citation><ArticleIdList><ArticleId IdType="pubmed">28432138</ArticleId><ArticleId IdType="pmc">6596467</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordt EA, Clerc P, Roelofs BA, Saladino AJ, Tretter L, Adam-Vizi V et al (2017) The putative Drp1 inhibitor mdivi-1 is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species. Dev Cell 40(6):583&#x2013;594 e6</Citation><ArticleIdList><ArticleId IdType="pubmed">28350990</ArticleId><ArticleId IdType="pmc">5398851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz A, Quintela-Lopez T, Sanchez-Gomez MV, Gaminde-Blasco A, Alberdi E, Matute C (2020) Mitochondrial division inhibitor 1 disrupts oligodendrocyte Ca(2+) homeostasis and mitochondrial function. Glia 68(9):1743&#x2013;1756</Citation><ArticleIdList><ArticleId IdType="pubmed">32060978</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y et al (2020) Therapeutic siRNA: state of the art. Signal Transduct Target Ther 5(1):101</Citation><ArticleIdList><ArticleId IdType="pubmed">32561705</ArticleId><ArticleId IdType="pmc">7305320</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott LJ (2020) Givosiran: First Approval. Drugs 80(3):335&#x2013;339</Citation><ArticleIdList><ArticleId IdType="pubmed">32034693</ArticleId></ArticleIdList></Reference><Reference><Citation>Urits I, Swanson D, Swett MC, Patel A, Berardino K, Amgalan A et al (2020) A review of patisiran (ONPATTRO(R)) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther 9(2):301&#x2013;315</Citation><ArticleIdList><ArticleId IdType="pubmed">32785879</ArticleId><ArticleId IdType="pmc">7606409</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata M, Watanabe S, Yamane A, Miyasaka T, Misonou H (2019) Regulatory mechanisms for the axonal localization of tau protein in neurons. Mol Biol Cell 30(19):2441&#x2013;2457</Citation><ArticleIdList><ArticleId IdType="pubmed">31364926</ArticleId><ArticleId IdType="pmc">6743362</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlen KM, Roush EC, Clayton JE, Martinka S, Hughes TE (2019) Live-cell assays for cell stress responses reveal new patterns of cell signaling caused by mutations in rhodopsin, alpha-synuclein and TDP-43. Front Cell Neurosci 13:535</Citation><ArticleIdList><ArticleId IdType="pubmed">31920544</ArticleId><ArticleId IdType="pmc">6930162</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Bao P, Jiang X et al (2019) Reactivation of nonsense-mediated mRNA decay protects against C9orf72 dipeptide-repeat neurotoxicity. Brain 142(5):1349&#x2013;1364</Citation><ArticleIdList><ArticleId IdType="pubmed">30938419</ArticleId><ArticleId IdType="pmc">6487333</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero EN, Mitra J, Wang H et al (2019) Amyotrophic lateral sclerosis- associated TDP-43 mutation Q331K prevents nuclear translocation of XRCC4-DNA ligase 4 complex and is linked to genome damage- mediated neuronal apoptosis. Hum Mol Genet 28(5):2459&#x2013;2476</Citation><ArticleIdList><ArticleId IdType="pubmed">31067307</ArticleId><ArticleId IdType="pmc">6659010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A, Rayner SL, Gwee SSL et al (2018) Pathogenic mutation in the ALS/- FTD gene, CCNF, causes elevated Lys48-linked ubiquitylation and defective autophagy. Cell Mol Life Sci 75(2):335&#x2013;354</Citation><ArticleIdList><ArticleId IdType="pubmed">28852778</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>